3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
7
Unknown
3
Not yet recruiting
1
Available
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
2
Burkitt Lymphoma
2
Recurrence
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia
1
Carcinoma, Pancreatic Ductal
1
Interventions
Cyclophosphamide
6
fludarabine
5
toripalimab
3
Paclitaxel
3
Etoposide
3
Carboplatin
3
Bevacizumab
3
zimberelimab
2
tislelizumab
2
sintilimab
2
glumetinib
2
Vincristine
2
Temozolomide
2
Platinum
2
Immune Checkpoint Inhibitors
2
Hepatectomy
2
Gemcitabine
2
Drug Therapy
2
Docetaxel
2
Cisplatin
2
Capecitabine
2
venetoclax
1
relmacabtagene autoleucel
1
osimertinib
1
lenvatinib
1
irinotecan sucrosofate
1
glofitamab
1
gallium maltolate
1
fludarabine phosphate
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Recurrence
×
Immunotherapy, Adoptive
×
Clear all
NCT06647329
2024-10-17
CAR-T Therapy
Zhengzhou University
Phase 1
Not yet recruiting
30 enrolled